News | VIVA | October 05, 2020

The Latest Vascular Interventional Clinical Data Presented at VIVA 2020

Top 10 trials listed below will be presented live

The Latest Vascular Interventional Clinical Data Presented at VIVA 2020 late-breaking sessions

October 5, 2020 — The Vascular Interventional Advances (VIVA) virtual conference will feature 10 late-breaking clinical trials sessions during the virtual meeting Nov. 6-7, 2020. A multidisciplinary, international panel of expert physicians, scientists and regulators will ask questions and shed light on the lasting impact of the research results as they are presented for the first time. 

For more information: https://vivaphysicians.org/clinical-trials

Friday, Nov. 6, 
Session beginning at 11 a.m. PT

   • 5-Year Outcomes from the IN.PACT Global Study. Presented by Thomas Zeller, M.D., Ph.D.

   • Drug-Coated Devices & Limb Outcomes After Endovascular Peripheral Artery Revascularizations. Presented by Connie N. Hess, M.D., MHS.

   • Standard vs Ultrasound-Assisted Thrombolysis for Submassive Pulmonary Embolism. Presented by Efthymios Avgerinos, M.D., Ph.D., MSc.

   • VIVO Study 12-Month Endpoint Results. Presented by Anthony Comerota, M.D.

   • PROMISE I 1-Year Results. Presented by Daniel Clair, M.D.

Saturday, Nov. 7 
Session beginning at 7 a.m. PT

   • DISRUPT PAD III RCT Acute Results: IVL vs PTA in Severe Calcium. Presented by William A. Gray, M.D.

   • REALITY Study: Directional Atherectomy Vessel Preparation Prior to DCB Angioplasty. Presented by Krishna Rocha-Singh, M.D.

   • 24-Month Outcomes from the DETOUR 1 Trial for Percutaneous Femoropopliteal Bypass. Presented by Ehrin Armstrong, M.D.

   • 2-Year Outcomes of a Multi-Centre Study on Infrapopliteal Bioresorbable Vascular Scaffold. Presented by Steven Kum, M.D.

   • 4-Year DCB Mortality Across ILLUMENATE RCTs. Presented by Sean Lyden, M.D.

 

Related VIVA Conference Content:

VIVA 2019 Late-breaking Clinical Trials

Other VIVA news


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now